Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Why Exelixis (EXEL) Might Surprise This Earnings Season
10:32am, Monday, 09'th May 2022
Exelixis (EXEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
10:20am, Friday, 06'th May 2022 Zacks Investment Research
Smart Beta ETF report for FBT
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
10:20am, Wednesday, 04'th May 2022 Zacks Investment Research
Sector ETF report for XBI
3 Growth Stocks to Buy With $1,000 Right Now
02:00pm, Tuesday, 03'rd May 2022 The Motley Fool
A small investment can go a long way.
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
01:01pm, Tuesday, 03'rd May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Acadia Announces FDA AdComm For Pimavanserin In Alzheimer's-Related Psychosis
The FDA's Psychopharmaco
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
01:40pm, Friday, 29'th Apr 2022 Zacks Investment Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's How Much You'd Have If You Invested $1000 in Exelixis a Decade Ago
12:30pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Exelixis: Beyond The Cabozantinib Franchise
12:06pm, Thursday, 21'st Apr 2022
Driven by their blockbuster Cabo, Exelixis generated $1.43B in total revenues translating to a 45.3% year-over-year (YOY) increase. For further growth, the company is expanding Cabo's label in multipl
Exelixis (EXEL) Outperforms Industry YTD: What Lies Ahead?
03:50pm, Tuesday, 19'th Apr 2022 Zacks Investment Research
Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.
Exelixis (EXEL) Outperforms Industry YTD: What Lies Ahead?
01:33pm, Tuesday, 19'th Apr 2022
Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.
Exelixis (EXEL) Initiates Early Stage Study of Lymphoma
04:45pm, Monday, 18'th Apr 2022 Zacks Investment Research
Exelixis (EXEL) commences the dose-escalation stage of the phase I study of XL114 in patients with non-Hodgkin's lymphoma.
Exelixis (EXEL) Initiates Early Stage Study of Lymphoma
02:18pm, Monday, 18'th Apr 2022
Exelixis (EXEL) commences the dose-escalation stage of the phase I study of XL114 in patients with non-Hodgkin's lymphoma.
Nasdaq Bear Market: 3 of the Safest Stocks to Buy on the Dip
09:05am, Wednesday, 13'th Apr 2022 The Motley Fool
A tumbling market is the perfect time to invest in these pillars of stability.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
01:45pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
11:17am, Tuesday, 12'th Apr 2022
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
